Sepsis: Threat to Cardiovascular Health (CE Session)
Includes a Live Web Event on 09/25/2024 at 11:45 AM (PDT)
Description:
Date/Time: September 25, 2024 | 2:45 - 3:30 pm ET
Sepsis is associated with an increased risk of heart failure, atrial fibrillation, stroke, and other cardiovascular complications. This presentation will discuss the epidemiology of sepsis-associated cardiovascular disease, the concepts of cardiovascular risk factors and triggers, and the mechanisms by which sepsis may increase cardiovascular risk. In addition, the presenter will address the clinical implications of the association between sepsis and cardiovascular disease and outline areas for future research and clinical trials. Where appropriate, recommendations from clinical practice guidelines will be discussed.
Learning Objectives:
At the end of this session, the learner should be able to:
- Critically appraise the data on epidemiology of sepsis and cardiovascular disease;
- Describe the potential mechanisms by which sepsis may lead to cardiovascular risk;
- Review evidence-based recommendations to prevent and manage cardiovascular disease related to sepsis.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Mitchell S. V. Elkind, MD, MS, FAHA
Chief Clinical Science Officer
American Heart Association
Mitchell Elkind, MD, MS, FAHA, is the American Heart Association’s Chief Clinical Science Officer and serves as the senior staff science leader for all Association initiatives related to stroke, brain health, and new integrated efforts including cardio-renal-metabolic health. Previously, he was president of the American Heart Association for 2020-21, a tenured Professor of Neurology and Epidemiology, and Chief of the Division of Neurology Clinical Outcomes Research and Population Sciences in the Neurology Department at Columbia University.
As Chief Clinical Science Officer, Dr. Elkind’s trusted voice, collaborative approach, and extensive clinical knowledge and experience are instrumental to ensuring the Association’s next generation research efforts are patient-centered, highly participatory, and inclusive of all populations.
Dr. Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. He is a principal investigator of federally-funded studies examining atrial cardiopathy in cryptogenic stroke; stroke risk factors; short-term high-dose statin therapy in acute stroke; and inflammation in stroke treatment.
Dr. Elkind has a longstanding commitment to medical education and research training. In addition to leading the Columbia Neurology residency and fellowship programs, he served as editor of the AHA/ASA Stroke journal’s International Stroke Early Career and Training Section. He also runs National Institutes of Health-funded research training programs for residents and fellows.
As a long-time AHA volunteer, Dr. Elkind has served on numerous leadership committees, including three terms on the National Board of Directors, two terms as chairperson of the ASA Advisory Committee (2016-20), and is a past chairperson of the Science Advisory and Coordinating Committee (2020-21), Manuscript Oversight Committee, Awards Subcommittee, and a past co-chair of the Governance Committee (2021-22). He has also served on numerous writing committees for guidelines and scientific statements including co-chairing the writing committee for the 2012 scientific statement on the inclusion of stroke as an outcome and risk equivalent in vascular disease risk scores.
In 2021, Dr. Elkind was honored with the Association’s Distinguished National Leadership Award for his significant contributions to our mission, especially in response to the global COVID-19 pandemic.
Summit 2024 Session: Sepsis: Threat to Cardiovascular Health (CE Session)
Session Day/Time: Wednesday, September 25, 2024, 2:45 PM - 3:30 PM EST
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 0.6 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.5 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.